JP2006516113A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006516113A5 JP2006516113A5 JP2004533177A JP2004533177A JP2006516113A5 JP 2006516113 A5 JP2006516113 A5 JP 2006516113A5 JP 2004533177 A JP2004533177 A JP 2004533177A JP 2004533177 A JP2004533177 A JP 2004533177A JP 2006516113 A5 JP2006516113 A5 JP 2006516113A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- protein
- thrombolytic
- linker peptide
- hirudin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 claims description 36
- 102000037865 fusion proteins Human genes 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 108010007267 Hirudins Proteins 0.000 claims description 13
- 230000002537 thrombolytic effect Effects 0.000 claims description 13
- JYPCXBJRLBHWME-IUCAKERBSA-N Gly-Pro-Arg Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JYPCXBJRLBHWME-IUCAKERBSA-N 0.000 claims description 11
- 239000003146 anticoagulant agent Substances 0.000 claims description 11
- 102000007625 Hirudins Human genes 0.000 claims description 10
- 101710145796 Staphylokinase Proteins 0.000 claims description 10
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 10
- 229940006607 hirudin Drugs 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 239000002506 anticoagulant protein Substances 0.000 claims description 8
- 239000003114 blood coagulation factor Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 229940019700 blood coagulation factors Drugs 0.000 claims description 3
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 2
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims description 2
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 claims description 2
- 108010025801 glycyl-prolyl-arginine Proteins 0.000 claims description 2
- 229940127126 plasminogen activator Drugs 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 108010023197 Streptokinase Proteins 0.000 claims 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 229960005202 streptokinase Drugs 0.000 claims 2
- 231100000167 toxic agent Toxicity 0.000 claims 2
- 239000003440 toxic substance Substances 0.000 claims 2
- 229960005356 urokinase Drugs 0.000 claims 2
- 102000004411 Antithrombin III Human genes 0.000 claims 1
- 108090000935 Antithrombin III Proteins 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 229960005348 antithrombin iii Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000014508 negative regulation of coagulation Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 101150010939 tpa gene Proteins 0.000 description 3
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101150063409 Fh gene Proteins 0.000 description 1
- 101150118163 h gene Proteins 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021290865A CN1480466A (zh) | 2002-09-03 | 2002-09-03 | 一类溶栓抗凝双功能融合蛋白及应用 |
| PCT/CN2003/000743 WO2004022598A1 (fr) | 2002-09-03 | 2003-09-03 | Proteine hybride assurant les fonctions d'hemolyse et d'anticoagulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010106629A Division JP2010184930A (ja) | 2002-09-03 | 2010-05-06 | 血栓溶解および抗凝固両方の機能を有する融合タンパク質、ならびにその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006516113A JP2006516113A (ja) | 2006-06-22 |
| JP2006516113A5 true JP2006516113A5 (enExample) | 2006-12-07 |
Family
ID=31954566
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004533177A Pending JP2006516113A (ja) | 2002-09-03 | 2003-09-03 | 血栓溶解および抗凝固両方の機能を有する融合タンパク質、ならびにその使用 |
| JP2010106629A Pending JP2010184930A (ja) | 2002-09-03 | 2010-05-06 | 血栓溶解および抗凝固両方の機能を有する融合タンパク質、ならびにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010106629A Pending JP2010184930A (ja) | 2002-09-03 | 2010-05-06 | 血栓溶解および抗凝固両方の機能を有する融合タンパク質、ならびにその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8212003B2 (enExample) |
| EP (1) | EP1541589B1 (enExample) |
| JP (2) | JP2006516113A (enExample) |
| CN (2) | CN1480466A (enExample) |
| AT (1) | ATE376001T1 (enExample) |
| AU (1) | AU2003261606A1 (enExample) |
| DE (1) | DE60316967T2 (enExample) |
| WO (1) | WO2004022598A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102443065A (zh) * | 2005-06-01 | 2012-05-09 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 特异性抗凝血物质的制备及其应用 |
| CN1896108B (zh) * | 2005-06-01 | 2012-01-04 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 特异性抗凝血物质的制备及其应用 |
| EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| US8968728B2 (en) * | 2006-05-12 | 2015-03-03 | Bharat Biotech International Limited | Chimeric fusion proteins |
| ATE533789T1 (de) | 2006-12-15 | 2011-12-15 | Inst Radiation Med Amms Pla | Herstellung von mit geringen blutungen assoziiertem gerinnungshemmendem fusionsprotein und dessen verwendung |
| CN100519585C (zh) * | 2007-02-06 | 2009-07-29 | 中国人民解放军军事医学科学院基础医学研究所 | P11与sak的融合蛋白及其制备方法和用途 |
| JP2010518039A (ja) * | 2007-02-12 | 2010-05-27 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | カザールタイプ・セリン・プロテアーゼ阻害剤の治療への応用 |
| PT3078743T (pt) * | 2007-09-28 | 2020-07-15 | Portola Pharm Inc | Antídotos para inibidores do fator xa e métodos de utilização dos mesmos |
| DE102009010611A1 (de) * | 2009-02-25 | 2010-08-26 | Siemens Aktiengesellschaft | Vorrichtung und Verfahren zur Steuerung einer mit mehreren Brennern ausgestatteten Turbine für flüssige oder gasförmige Brennstoffe |
| JP6234224B2 (ja) * | 2010-08-05 | 2017-11-22 | カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ | 血栓溶解及び抗凝固特性を有するタンパク質融合構築物 |
| CN102180973B (zh) * | 2011-03-18 | 2012-08-29 | 重庆大学 | 靶向多功能防栓融合蛋白及其制备方法和应用 |
| JP2015533483A (ja) * | 2012-09-07 | 2015-11-26 | サノフイ | メタボリックシンドロームを治療するための融合タンパク質 |
| CN106366200B (zh) * | 2015-07-23 | 2020-04-10 | 武汉光谷人福生物医药有限公司 | 制备重组葡激酶-水蛭素融合蛋白的方法 |
| JP7028904B2 (ja) * | 2019-03-21 | 2022-03-02 | アカデミア シニカ | 合成ペプチド、それを備える薬学的組成物及び血栓塞栓症関連疾患の治療におけるその使用 |
| CN113150168B (zh) * | 2021-01-29 | 2022-11-11 | 武汉真福医药股份有限公司 | 一种qk纤溶酶基因-水蛭素融合蛋白的制备方法及应用 |
| KR102789819B1 (ko) * | 2021-10-21 | 2025-03-31 | 중앙대학교 산학협력단 | 트롬빈 검출용 신규한 펩타이드 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5298599A (en) * | 1988-12-30 | 1994-03-29 | Oklahoma Medical Research Foundation | Expression and purification of recombinant soluble tissue factor |
| GB8927722D0 (en) * | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
| US5759542A (en) * | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US6015787A (en) * | 1997-11-04 | 2000-01-18 | New England Medical Center Hospitals, Inc. | Cell-permeable protein inhibitors of calpain |
| US6423680B1 (en) * | 1998-10-30 | 2002-07-23 | Hsc Research And Development Limited Partnership | Inhibitor of platelet activating factor |
| CN1188522C (zh) * | 2001-07-20 | 2005-02-09 | 健力福生化技术（上海）有限公司 | 一种血栓靶向性溶栓蛋白表达质粒及其构建 |
| CN1181099C (zh) * | 2002-07-23 | 2004-12-22 | 中国人民解放军第二军医大学 | 兼抗凝溶栓双重功能的血栓靶向融合蛋白mA5UKB |
-
2002
- 2002-09-03 CN CNA021290865A patent/CN1480466A/zh active Pending
-
2003
- 2003-09-03 WO PCT/CN2003/000743 patent/WO2004022598A1/zh not_active Ceased
- 2003-09-03 DE DE60316967T patent/DE60316967T2/de not_active Expired - Lifetime
- 2003-09-03 AT AT03793572T patent/ATE376001T1/de not_active IP Right Cessation
- 2003-09-03 JP JP2004533177A patent/JP2006516113A/ja active Pending
- 2003-09-03 CN CNB038207729A patent/CN1301268C/zh not_active Expired - Fee Related
- 2003-09-03 US US10/526,682 patent/US8212003B2/en not_active Expired - Fee Related
- 2003-09-03 EP EP03793572A patent/EP1541589B1/en not_active Expired - Lifetime
- 2003-09-03 AU AU2003261606A patent/AU2003261606A1/en not_active Abandoned
-
2010
- 2010-05-06 JP JP2010106629A patent/JP2010184930A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5759542A (en) | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases | |
| JP2580141B2 (ja) | 形質転換された酵母及びヒルジンの製造方法 | |
| JP2006516113A5 (enExample) | ||
| US5632986A (en) | Phospholipid-targeted thrombolytic agents | |
| JP2010184930A (ja) | 血栓溶解および抗凝固両方の機能を有する融合タンパク質、ならびにその使用 | |
| IL96601A (en) | Plasminogen analogues activatable by thrombin or factor xa | |
| JPS63503275A (ja) | ファクター８：ｃの製造方法 | |
| JPH06503474A (ja) | トロンビンおよび血小板活性化の二機能性阻害剤 | |
| JPH11504938A (ja) | クニッツ型プロテアーゼ阻害因子 | |
| JPWO1992000325A1 (ja) | 抗血液凝固活性を有するポリペプチド | |
| ES2235153T3 (es) | Dominios terapeuticos del factor de von willebrand. | |
| EP0538459A1 (en) | Phospholipid-targeted thrombolytic agents | |
| US7163817B2 (en) | Clot-specific streptokinase proteins possessing altered plasminogen activation characteristics and a process for their preparation | |
| RU2283863C2 (ru) | Рекомбинантное производное стафилокиназы, его получение и применение | |
| JP6234224B2 (ja) | 血栓溶解及び抗凝固特性を有するタンパク質融合構築物 | |
| JPH04505554A (ja) | 可溶性トロンボモジュリン類似体 | |
| JP5345069B2 (ja) | 低出血性抗凝固性融合タンパク質の調製および使用 | |
| JPH10262668A (ja) | 血管形成誘導因子をコードするタンパク質コード配列を包含するｄｎａ配列 | |
| JPS6248378A (ja) | 新規な組織プラスミノーゲン活性化因子誘導体 | |
| JP2942578B2 (ja) | 新しい結合特性を有する超酸化物不均化酵素類縁体 | |
| CA2150909A1 (en) | Clotting inhibitor made from protostomia saliva | |
| JPH04505698A (ja) | ヒトフィブロネクチンポリペプチド類似体のクローニング及び製造並びにこのようなポリペプチド類似体の使用法 | |
| CN101848928B (zh) | 葡激酶变异体 | |
| JPH02295483A (ja) | Ｔｐａのプロテアーゼ領域中に位置する修飾残基をコードする新しい遺伝子配列 | |
| AU619803B2 (en) | Rearranged tissue plasminogen activators and method for producing same |